Form 4: CEO Acquires Shares in Vyome Holdings Post-Merger

Vyome Holdings' President and CEO, Nelabhotla Venkateswarlu, acquired 7 shares of common stock following the merger with Vyome Therapeutics.

Summary

• Nelabhotla Venkateswarlu, who serves as President and CEO, Director, and a 10% Owner of Vyome Holdings, Inc., acquired 7 shares of the company's common stock.
• This acquisition took place on August 15, 2025, as a direct consequence of a merger transaction.
• The merger involved Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer, merging with Vyome Therapeutics, Inc., with Vyome Therapeutics surviving as a subsidiary of Vyome Holdings, Inc.
• Under the terms of the merger agreement, each 5,000 shares of Vyome Therapeutics common or preferred stock were converted into 1 share of Vyome Holdings common stock.
• Mr. Venkateswarlu exchanged 35,000 shares of Vyome Therapeutics common stock to receive the 7 shares of Vyome Holdings common stock.
• Following the completion of the merger, the Issuer was officially renamed "Vyome Holdings, Inc."

Sentiment

Score: 7

Explanation: The completion of a merger and the CEO's resulting share ownership are generally positive indicators of strategic progress and alignment of interests, though the filing itself is purely factual and transactional.

Positives

• The completion of the merger with Vyome Therapeutics, Inc. signifies a strategic expansion or consolidation for Vyome Holdings, Inc.
• The CEO's acquisition of shares, resulting from the merger conversion, aligns his financial interests with those of the shareholders in the newly structured entity.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the completion of the merger and the resulting corporate structure.

Industry Context

This filing indicates a consolidation within the life sciences or pharmaceutical sector, with Vyome Holdings acquiring Vyome Therapeutics. Such mergers are common for expanding product pipelines, market reach, or technological capabilities, reflecting a strategic move to enhance market position or operational synergies.

Comparison to Industry Standards

• This Form 4 filing primarily reports a change in beneficial ownership due to a merger and does not contain sufficient financial or operational data to compare specific results or metrics against industry benchmarks or comparable companies.

Corporate Governance

Related Party Transactions

• The merger involved Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer, merging with Vyome Therapeutics, Inc. The share conversion for the CEO is a direct result of the merger terms.

Stakeholder Impact

• Shareholders of Vyome Therapeutics had their shares converted into Vyome Holdings common stock, altering their investment vehicle.
• Shareholders of the original Issuer now own a company with a new name and an expanded operational scope through the new subsidiary.
• Employees of Vyome Therapeutics are now part of a larger organizational structure under Vyome Holdings, Inc.

Next Steps

• Integration of Vyome Therapeutics as a subsidiary of Vyome Holdings, Inc.
• Ongoing operations of the combined entity under the new corporate structure.

Key Dates

Keywords

Vyome Holdings, HIND, Nelabhotla Venkateswarlu, Merger, Vyome Therapeutics, Share Acquisition, CEO, Director, Beneficial Ownership, SEC Form 4